Literature DB >> 34738828

Comparison of a Pure Plug-Based Versus a Primary Suture-Based Vascular Closure Device Strategy for Transfemoral Transcatheter Aortic Valve Replacement: The CHOICE-CLOSURE Randomized Clinical Trial.

Mohamed Abdel-Wahab1, Philipp Hartung1, Oliver Dumpies1, Danilo Obradovic1, Johannes Wilde1, Nicolas Majunke1, Peter Boekstegers2,3, Ralf Müller2, Melchior Seyfarth3,4, Marc Vorpahl3,4, Philipp Kiefer5, Thilo Noack5, Sergey Leontyev5, Marcus Sandri1, Johannes Rotta Detto Loria1, Mitsunobu Kitamura1, Michael Andrew Borger5, Anne-Kathrin Funkat6, Sven Hohenstein1, Steffen Desch1, David Holzhey5,7, Holger Thiele1.   

Abstract

BACKGROUND: Transcatheter aortic valve replacement is an established treatment option for patients with severe symptomatic aortic stenosis and is most commonly performed through the transfemoral access route. Percutaneous access site closure can be achieved using dedicated plug-based or suture-based vascular closure device (VCD) strategies, but randomized comparative studies are scarce.
METHODS: The CHOICE-CLOSURE trial (Randomized Comparison of Catheter-based Strategies for Interventional Access Site Closure during Transfemoral Transcatheter Aortic Valve Implantation) is an investigator-initiated, multicenter study, in which patients undergoing transfemoral transcatheter aortic valve replacement were randomly assigned to vascular access site closure using either a pure plug-based technique (MANTA, Teleflex) with no additional VCDs or a primary suture-based technique (ProGlide, Abbott Vascular) potentially complemented by a small plug. The primary end point consisted of access site- or access-related major and minor vascular complications during index hospitalization, defined according to the Valve Academic Research Consortium-2 criteria. Secondary end points included the rate of access site- or access-related bleeding, VCD failure, and time to hemostasis.
RESULTS: A total of 516 patients were included and randomly assigned. The mean age of the study population was 80.5±6.1 years, 55.4% were male, 7.6% of patients had peripheral vascular disease, and the mean Society of Thoracic Surgeons score was 4.1±2.9%. The primary end point occurred in 19.4% (50/258) of the pure plug-based group and 12.0% (31/258) of the primary suture-based group (relative risk, 1.61 [95% CI, 1.07-2.44], P=0.029). Access site- or access-related bleeding occurred in 11.6% versus 7.4% (relative risk, 1.58 [95%CI: 0.91-2.73], P=0.133) and device failure in 4.7% versus 5.4% (relative risk, 0.86, [95% CI, 0.40-1.82], P=0.841) in the respective groups. Time to hemostasis was significantly shorter in the pure plug-based group (80 [32-180] versus 240 [174-316] seconds, P<0.001).
CONCLUSIONS: Among patients treated with transfemoral transcatheter aortic valve replacement, a pure plug-based vascular closure technique using the MANTA VCD is associated with a higher rate of access site- or access-related vascular complications but a shorter time to hemostasis compared with a primary suture-based technique using the ProGlide VCD. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04459208.

Entities:  

Keywords:  randomized control trial; sutures; transcatheter aortic valve replacement; vascular closure devices

Mesh:

Year:  2021        PMID: 34738828     DOI: 10.1161/CIRCULATIONAHA.121.057856

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Successful management of a bleeding complication during transaxillary transcatheter aortic-valve implantation: a case report.

Authors:  Philipp Lauten; Mohamed El-Garhy; Mahmoud Al-Jassem; Harald Lapp
Journal:  Eur Heart J Case Rep       Date:  2022-07-05

2.  A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation.

Authors:  Gregor Heitzinger; Christina Brunner; Sophia Koschatko; Varius Dannenberg; Katharina Mascherbauer; Kseniya Halavina; Carolina Doná; Matthias Koschutnik; Georg Spinka; Christian Nitsche; Markus Mach; Martin Andreas; Florian Wolf; Christian Loewe; Christoph Neumayer; Michael Gschwandtner; Andrea Willfort-Ehringer; Max-Paul Winter; Irene M Lang; Philipp E Bartko; Christian Hengstenberg; Georg Goliasch
Journal:  Front Cardiovasc Med       Date:  2022-01-21

3.  Real-World Experience With a Large Bore Vascular Closure Device During TAVI Procedure: Features and Predictors of Access-Site Vascular Complications.

Authors:  Giulia Masiero; Livio D'Angelo; Luca Nai Fovino; Tommaso Fabris; Francesco Cardaioli; Giulio Rodinò; Alice Benedetti; Mauro Boiago; Saverio Continisio; Carolina Montonati; Tommaso Sciarretta; Vittorio Zuccarelli; Andrea Scotti; Giulia Lorenzoni; Andrea Pavei; Massimo Napodano; Chiara Fraccaro; Sabino Iliceto; Alfredo Marchese; Giovanni Esposito; Giuseppe Tarantini
Journal:  Front Cardiovasc Med       Date:  2022-02-28

Review 4.  Advances in Clinical Cardiology 2021: A Summary of Key Clinical Trials.

Authors:  Patrick Savage; Brian Cox; Katie Linden; Jaimie Coburn; Michael Shahmohammadi; Ian Menown
Journal:  Adv Ther       Date:  2022-04-28       Impact factor: 4.070

5.  Large-bore arterial access closure after transcatheter aortic valve replacement: a systematic review and network meta-analysis.

Authors:  Claudio Montalto; Andrea Raffaele Munafò; Luca Arzuffi; Francesco Soriano; Antonio Mangieri; Stefano Nava; Giovanni Luigi De Maria; Francesco Burzotta; Fabrizio D'Ascenzo; Antonio Colombo; Azeem Latib; Jacopo Andrea Oreglia; Adrian P Banning; Italo Porto; Gabriele Crimi
Journal:  Eur Heart J Open       Date:  2022-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.